Heart failure hope for Novartis first-in-class neprilysin inhibitor
This article was originally published in Scrip
Executive Summary
Novartis may be able to plug the gap in treatments for heart failure with preserved ejection fraction with its novel product LCZ696, based on positive effects on a surrogate marker in a Phase II trial presented this weekend at the European Society of Cardiology meeting in Munich.
You may also be interested in...
Novartis’s Entresto PARAGON-HF Miss Puts Large Commercial Opportunity At Risk
Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.